



CFBD Seminar Series

Thursday, 3 February 2022, 7:00 – 8:30 pm AEDT, [Zoom](#)

Drug Discovery in High Definition



Dr Giles Brown joined Dunad Therapeutics, as Senior Vice President, Medicinal Chemistry in Jan 2022 to develop the next-generation of targeted protein degradation therapies. Prior to this, he spent over 3 years at OMass Therapeutics as Vice President, Medicinal Chemistry helping to build the organisation and utilize the companies novel native mass spectrometry platform in drug discovery. He joined OMass from Heptares Therapeutics where he held the position as Head of Medicinal Chemistry. He joined the company in 2010 to help develop the StaR[®] structural biology platform as a new approach to structure-based drug design and lead identification for GPCRs. He co-lead the teams which identified the first selective M1 (HTL9936 and HTL18318) and M4 (HTL16878) agonists taken into clinical development for the treatment of cognition in Alzheimer's disease. He is also a co-inventor of the A2A antagonist, Imaradenant, an immuno-oncology candidate taken into clinical development for metastatic castration-resistant prostate cancer (mCRPC) with AstraZeneca. Prior to Heptares he worked for Cambridge BioTechnology (which was acquired by BioVitrums in 2005) as a Medicinal Chemistry Team Leader to help establish the chemistry team and advance the internal pipeline. Previously he worked for Evotec OAI, as a Senior Scientist, a role he took on after completing a two-year postdoctoral position at the University of Pennsylvania in synthetic chemistry with Prof Gary Molander. He obtained his PhD in organic chemistry with Prof Tim Gallagher from the University of Bristol and has an MBA from Henley Business School at the University of Reading, he is a Fellow of the Royal Society of Chemistry. He is an author of over 60 patents and peer reviewed publications.